Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

Saved in:
Bibliographic Details
Title: Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Authors: Camidge DR; University of Colorado Cancer Center, Aurora, CO., Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Ahn MJ; Samsung Medical Center, Seoul, South Korea., Yang JCH; National Taiwan University Hospital, Taipei, Taiwan., Han JY; National Cancer Center, Goyang, South Korea., Hochmair MJ; Department of Respiratory and Critical Care Medicine, Krankenhaus Nord-Klinik Floridsdorf, Vienna, Austria., Lee KH; Chungbuk National University Hospital, Cheongju, South Korea., Delmonte A; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy., García Campelo MR; Complejo Hospitalario Universitario A Coruna, Coruna, Spain., Kim DW; Seoul National University Hospital, Seoul, South Korea., Griesinger F; Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany., Felip E; Vall d'Hebron University Hospital, Barcelona, Spain., Califano R; The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom., Spira A; Virginia Cancer Specialists and US Oncology Research, The Woodlands, TX., Gettinger SN; Yale Cancer Center, New Haven, CT., Tiseo M; University Hospital of Parma, Parma, Italy., Lin HM; Millennium Pharmaceuticals, Cambridge, MA., Gupta N; Millennium Pharmaceuticals, Cambridge, MA., Hanley MJ; Millennium Pharmaceuticals, Cambridge, MA., Ni Q; Millennium Pharmaceuticals, Cambridge, MA., Zhang P; Millennium Pharmaceuticals, Cambridge, MA., Popat S; Royal Marsden Hospital, London, United Kingdom.; The Institute of Cancer Research, London, United Kingdom.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Nov 01; Vol. 38 (31), pp. 3592-3603. Date of Electronic Publication: 2020 Aug 11.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.20.00505